MY133485A - Transdermal administration of reboxetine - Google Patents

Transdermal administration of reboxetine

Info

Publication number
MY133485A
MY133485A MYPI20006094A MYPI20006094A MY133485A MY 133485 A MY133485 A MY 133485A MY PI20006094 A MYPI20006094 A MY PI20006094A MY PI20006094 A MYPI20006094 A MY PI20006094A MY 133485 A MY133485 A MY 133485A
Authority
MY
Malaysia
Prior art keywords
disorders
disorder
reboxetine
transdermal administration
prodrugs
Prior art date
Application number
MYPI20006094A
Inventor
Ulla Hoeck
Bo Kreilgard
Helle Kristensen
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of MY133485A publication Critical patent/MY133485A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

DEVICE FOR TRANSDERMAL ADMINISTRATION OF REBOXETINE,OPTIONALLY ENCOMPASSING SALT, PRODRUGS AND METABOLITES THEREOF,METHOD FOR THE MANUFACTURING OF A MEDICAMENT TO BE ADMINISTERED TRANSDERMALLY,AND METHODS OF TREATING DEPRESSION AND/OR SYMPTOMS ASSOCIATED WITH THIS CONDITION AND/OR FOR TREATING ADDICTIVE DISORDERS AND WITHDRAWAL SYNDROMES,ADJUSTMENT DISORDERS,AGE-ASSOCIATED LEARNING AND METAL DISORDERS,ANOREXIA NERVOSA,APATHY,ATTENTION-DEFICIT DISORDERS DUE TO GENERAL MEDICAL CONDITIONS ,ATTENTION-DEFICIT HYPERACTIVITY DISORDERS,BIPOLAR DISORDERS, BULIMIA NERVOSA, CHRONIC FATIGUE SYNDROME, CONDUCT DISORDERS, CYCLOTHYMIC DISORDERS, DEPRESSION, DYSTHYMIC DISORDERS, FIBROMYALGIA AND OTHER SAMOTOFORM DISORDERS, STRESS INCONTINENCE, GENERALIZED ANXIETY DISORDERS, INHALATION DISORDERS, AN INTOXICATION DISORDERS, OBESITY, OBSESSIVE COMPULSIVE DISORDERS AND RELATED SPECTRUM DISORDERS, OPPOSITIONAL DEFIANT DISORDERS,PANIC DISORDER, PERIPHERAL NEUROPATHY, POST-TRAUMATIC STRESS DISORDER, PERMENSTRUAL DYSPHORIC DISORDER, PSYYYCHOTIC DISORDERS, SEASONAL AFFECTIVE DISORDER, SLEEP DISORDER, SOCIAL PHOBIA, SPECIFIC DEVELOPMENTAL DISORDERS AND SELECTIVE SEROTONIN REUPTAKE INHIBITION (SSRI) "POOP OUT" SYNDROME AND SYMPTOMS ASSOCIATED WITH THESE CONDITIONS, AND/OR FOR OBTAINING AN ANTI-RESERPINE AND/OR NORADRENALINE REUPTAKE INHIBITING EFFECT BY TRANSDERMAL ADMINISTRATION OF REBOXETINE, OPTIONALLY ENCOMPASSING SALTS, PRODRUGS AND METABOLITES THEREOF.
MYPI20006094A 1999-12-23 2000-12-21 Transdermal administration of reboxetine MY133485A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904750A SE9904750D0 (en) 1999-12-23 1999-12-23 New formulation, use and method

Publications (1)

Publication Number Publication Date
MY133485A true MY133485A (en) 2007-11-30

Family

ID=20418276

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20006094A MY133485A (en) 1999-12-23 2000-12-21 Transdermal administration of reboxetine

Country Status (7)

Country Link
EP (1) EP1244431A1 (en)
AR (1) AR026371A1 (en)
AU (1) AU1068101A (en)
MY (1) MY133485A (en)
PE (1) PE20011024A1 (en)
SE (1) SE9904750D0 (en)
WO (1) WO2001047503A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660109A (en) 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 Highly selective norepinephrine reuptake inhibitors and methods of using the same
DK1493442T3 (en) * 1999-07-01 2005-12-19 Pharmacia & Upjohn Co Llc Reboxetine for the treatment of peripheral neuropathy
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
TWI754702B (en) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 (aza)indole- and benzofuran-3-sulfonamides
DE102017127433A1 (en) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS based on adhesive plasticizer polymer matrices
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
TW202016088A (en) 2018-06-19 2020-05-01 德商Ｕｃｂ製藥有限公司 Pyridinyl and pyrazinyl-(aza)indolsulfonamides
EP3584244A1 (en) 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2020254289A1 (en) 2019-06-17 2020-12-24 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5155198A (en) * 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent

Also Published As

Publication number Publication date
PE20011024A1 (en) 2001-10-03
WO2001047503A1 (en) 2001-07-05
AR026371A1 (en) 2003-02-05
AU1068101A (en) 2001-07-09
SE9904750D0 (en) 1999-12-23
EP1244431A1 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
MY133485A (en) Transdermal administration of reboxetine
EA200801488A1 (en) SUBSTITUTED PHENETHYLAMINES OWNING SEROTONINERGIC AND / OR NOREPINEFININERGIC ACTIVITY
RS20120158A3 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
HRP20080478T3 (en) 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
JP2008524262A5 (en)
BRPI0507986A (en) compound, pharmaceutical composition, method for the treatment of obesity, obsessive compulsive disorder, depression, and anxiety in mammals, and, use of a compound
NO20010943L (en) Process for use and compositions including dopamine reuptake inhibitors
MX2021006985A (en) Methods for the treatment of depression.
MX2012014934A (en) Cyclohexyl-azetidinyl antagonists of ccr2.
MX2007006082A (en) Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin.
HRP20080262T3 (en) 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
WO2007058998A3 (en) Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
EA200101110A1 (en) NEW PHARMACEUTICAL COMBINATIONS OF NOS INHIBITORS
JP2012526775A5 (en)
BR0209342A (en) Azaheterocyclylmethyl antidepressants derived from 2,3 dihydro-1,4-dioxino [2,3-f] quinoxaline; method of treatment using such compounds; process to prepare them
PT1392700E (en) 7,8-DIHYDRO-1,6,9-TROXA-3-AZA-CICLOPENTA (A) NAFTALENE AZA-HETEROCYCLILLYTE DERIVATIVES
DE60312874D1 (en) COMBINATION THERAPY USING A SEROTONIN RECIPROCAL HEATER
WO2011156554A8 (en) Cyclohexyl-azetidinyl antagonists of ccr2
ZA200903652B (en) Methods for treating disruptive behavior disorders
NO20065809L (en) Preparation of New Substituted Haloar Compounds
NO20005621L (en) New drug combinations
EA201070736A1 (en) 4- [2,3-DIFFOR-6- (2-Fluoro-4-Methylphenylsulfanyl) phenyl] piperidine
WO2007047575A3 (en) Pharmacological treatments for sleep-related breathing disorders
CY1116959T1 (en) Substituted PHAs with serotoninergic and / or Norepinephrine activity
WO2007041257A3 (en) Substituted propylamine derivatives and methods of their use